Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34

Benzinga · 1d ago
Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and lowers the price target from $41 to $34.